Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vericel Corp (NASDAQ:VCEL)

3.39
Delayed Data
As of Jul 31
 +0.03 / +0.89%
Today’s Change
2.55
Today|||52-Week Range
4.35
+11.51%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$80.6M

Company Description

Vericel Corp. engages in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two cell therapy products in the United States, Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.Vericel was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Contact Information

Vericel Corp.
64 Sidney Street
Cambridge Massachusetts 02139
P:(617) 588-5555
Investor Relations:

Employees

Shareholders

Other institutional52.32%
Mutual fund holders3.71%
Individual stakeholders0.22%

Top Executives

Dominick C. ColangeloPresident & Chief Executive Officer
Daniel R. OrlandoChief Operating Officer
Gerard J. MichelChief Financial Officer & VP-Corporate Development
David ReckerChief Medical Officer
Ross TuboChief Scientific Officer